HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Suven Life Sciences to report net profit at Rs. 40 crore up 12.2% year-on-year (down 8.3% quarter-on-quarter).
Net Sales are expected to increase by 38.8 percent Y-o-Y (down 22.6 percent Q-o-Q) to Rs. 150 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 19.6 percent Y-o-Y (down 7.6 percent Q-o-Q) to Rs. 50 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
